沉默的基因，百亿的战争：小核酸技术破壁敲开药物新世界大门丨黄金眼

Group 1 - The "small nucleic acid" sector is gaining significant attention and investment, moving from laboratory research to the forefront of the industry [1] - Traditional drugs struggle with over 80% of disease-related targets being "undruggable," while small nucleic acid drugs offer a new approach by targeting the "blueprints" of disease-causing genes [2][3] - Small nucleic acid drugs, such as ASO and siRNA, can silence or regulate the expression of pathogenic genes, providing new treatment pathways for diseases like spinal muscular atrophy [4] Group 2 - The delivery system is a critical bottleneck for the development of small nucleic acid drugs, with recent advancements enabling targeting beyond the liver to other organs [5] - The FDA has approved 19 small nucleic acid drugs globally, with ASO and siRNA making up 38% and 32% of the development focus, respectively [5] - The pipeline for siRNA drugs is expanding into chronic diseases and CNS disorders, with significant applications in metabolic and cardiovascular diseases [6] Group 3 - The global market for small nucleic acid drugs is projected to grow from $2.7 billion in 2019 to $5.7 billion in 2024, with a compound annual growth rate (CAGR) of 16.2% [8] - The siRNA market share is expected to increase significantly, from $200 million in 2019 (7% share) to $2.4 billion in 2024 (44.5% share) [9] - Chinese companies are increasingly recognized for their innovation in small nucleic acids, with significant licensing deals and collaborations, marking a shift from following to competing in the global market [13] Group 4 - Notable acquisitions, such as Novartis's $12 billion purchase of Avidity, highlight the strategic importance of small nucleic acid platforms in drug delivery [8] - Companies like Be Better Med and Frontier Bio are developing diverse pipelines targeting various diseases, including hypertension and metabolic disorders [16][17] - The rise of small nucleic acids signifies a paradigm shift in drug discovery, moving from protein-based approaches to rational design based on genetic sequences [19]